Steward Partners Investment Advisory’s ProQR Therapeutics PRQR Stock Holding History

Steward Partners Investment Advisory’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.5K	Buy	35,241 +33,941	+2,611%	+$55.9K	﹤0.01%	2798
2026 Q1	$2.11K	Hold	1,300	–	–	﹤0.01%	4042
2025 Q4	$2.63K	Hold	1,300	–	–	﹤0.01%	3884
2025 Q3	$2.77K	Hold	1,300	–	–	﹤0.01%	3830
2025 Q2	$2.65K	Buy	1,300 +650	+100%	+$1.06K	﹤0.01%	3671
2025 Q1	$865	Sell	650 -1	-0.2%	-$2	﹤0.01%	3797
2024 Q4	$1.73K	Buy	+651	New	+$2.07K	﹤0.01%	3670

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Steward Partners Investment Advisory's PRQR Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its ProQR Therapeutics (PRQR) stake by 2,611% in Q2 2026, buying an estimated $55.9K and bringing the position to 35,241 shares worth $65.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2798.

Steward Partners Investment Advisory first reported a position in PRQR in Q4 2024 and has held it in 7 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Steward Partners Investment Advisory held 35,241 shares of ProQR Therapeutics worth $65.5K as of Q2 2026.
Steward Partners Investment Advisory bought 33,941 ProQR Therapeutics shares in Q2 2026, an estimated $55.9K.
ProQR Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #2798 holding.
Steward Partners Investment Advisory first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 7 quarters since.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.